EPISODE trial investigators

New Capabilities

As of September 2026: Reported inconclusive primary results in JAMA Psychiatry

The largest European trial of psilocybin for treatment-resistant depression failed its primary test. In results published this week in JAMA Psychiatry, 17% of patients who received one guided 25-milligram dose met the response threshold at six weeks, versus 10.6% on an active placebo. The gap missed statistical significance.

Updated Sep 17